Ajanta pharma Limited has announced key decisions regarding its employee incentive programs, with the company's Nomination and Remuneration Committee approving significant changes to Stock Appreciation Rights and Employee Stock Options under its Share Based Incentive Plan 2019.

Committee Approvals on Employee Incentives

The Nomination and Remuneration Committee of the Board of Directors convened on 30 January 2026 to deliberate on matters related to the company's Share Based Incentive Plan 2019. The meeting resulted in two major decisions affecting the company's employee compensation structure.

Stock Appreciation Rights Vesting Details

The committee approved the vesting of 4,300 cash-settled Stock Appreciation Rights scheduled for 31 January 2026. These SARs were originally granted to employees on 30 January 2025, representing a one-year vesting period.

The vested SARs will be settled in cash based on the closing market price of Ajanta Pharma's equity shares on stock exchanges as of 2 February 2026. Since these are cash-settled instruments, no new equity shares will be issued, ensuring no dilution of existing shareholding.

Employee Stock Options Cancellation

Simultaneously, the committee approved the cancellation of 800 stock options that were previously granted under the Share Based Incentive Plan 2019. The cancellation became necessary as the respective grantees ceased to be employees of the company prior to the vesting period.

The cancelled stock options have been credited back to the company's ESOP pool, making them available for future grants to eligible employees. This standard practice ensures efficient utilization of the company's employee incentive resources.

Regulatory Compliance

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was communicated to both BSE Limited and the National Stock Exchange of India, ensuring transparency in corporate governance practices related to employee compensation schemes.

Ajanta Pharma has reported robust financial results for the third quarter, showcasing strong operational performance with significant growth in profitability. The pharmaceutical company's consolidated net profit demonstrated healthy expansion compared to the corresponding period in the previous fiscal year.

Financial Performance Highlights

The company's third-quarter results reflect solid business momentum, with key financial metrics showing positive trajectory. The consolidated net profit figures indicate sustained growth in the company's core operations and effective management strategies.

Business Performance Analysis

The year-on-year comparison reveals Ajanta Pharma's ability to maintain growth momentum in its consolidated operations. The increase from ₹2.33 billion to ₹2.7 billion in net profit represents approximately 16% growth, indicating strong underlying business fundamentals and operational efficiency.

This financial performance reflects the company's continued focus on its pharmaceutical business segments and market expansion strategies. The positive growth trajectory in consolidated net profit suggests effective cost management and revenue optimization across the organization's various business verticals.